Two viewpoint articles published in JAMA Oncology provide opposing opinions on the benefit of testing for programmed death-ligand 1 (PD-L1) expression in patients with non-small-cell lung cancer ...

Factors Associated With Implementation of Biomarker Testing and Strategies to Improve Its Clinical Uptake in Cancer Care: Systematic Review Using Theoretical Domains Framework Observational studies or ...

Leronlimab increases PD-L1 expression on circulating tumor cells, potentially converting "cold" tumors to "hot" ones, enhancing immune response in metastatic triple-negative breast cancer. In a study, ...

Multikine reduced the risk of death by 66% compared to standard of care in the target population of patients with low and zero PD-L1, while Keytruda reduced the risk of recurrence and progression (EFS ...

PD-L1発現陽性の転移を有するトリプルネガティブ乳癌（TNBC）に対する1次治療として、抗PD-1抗体ペムブロリズマブと化学療法の併用療法は、CPS 10以上の患者が適切であることが明らかとなった。フェーズ3試験であるKEYNOTE-355試験の最終結果をCPS発現度合い別 ...

EINPresswire/ -- "Get 20% Off All Global Market Reports With Code ONLINE20 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors What Is The Expected Cagr For The PD-L1 And ...

Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 and TGF-beta, as a treatment for advanced gastric cancer. The green light – ...

Hematogenix, an industry leader in the field of integrated pathology services for drug development and immuno-oncology testing, announced the availability of the Ventana PD-L1 (SP142) and the PD-L1 ...